When: $345-355 retest of 200 SMA

Then: Add 35%

When: Confirmed close above $412-415 with volume ≥5M

Then: Add 30%

Wait for confirmation above $400 on closing basis with volume, or initiate smaller 15-20% starter position with same $345 stop rather than committing 35% upfront

• IRS dispute creates valuation overhang—markets price uncertainty with a discount; waiting for resolution compresses risk
• Q1 2026 $6.48B net income is one quarter not a trend; Trefis flags commercial cost trends still elevated with margin fix slipped
• Forward EPS $22.44 versus trailing $15.56 implies 44% growth already priced in—no margin of safety at current $392 entry
• Technical: price 4.8% below 50 SMA, 10 EMA declining $424 to $396, MACD negative at -5.35, RSI neutral at 42, below Bollinger middle band at $400
• Declining ATR and volume in downtrend signals consolidation, not reversal; prior $436 high dropped to $384 showing false capitulation patterns
• Low retail engagement means no marginal buyer stepping in—contrarian entry requires catalyst not present here
• Appaloosa full exit and Bretton Fund 10.67% vs S&P 15.20% underperformance are fund-flow signals, not noise
• Political/regulatory risks cumulative: IRS probe, prior authorization scrutiny, drug pricing reform, MA rate pressure—election cycle could amplify
• 35% Tranche 1 with $345 stop means 12% drawdown on initial tranche; third tranche requires confirmed reversal above $412-$415 not yet occurred
• High-quality compounder (Beta 0.63, 2.35% yield, $24B FCF, net debt/equity 0.5) pays you to wait—great company ≠ great trade right now

→ vs aggressive: IRS dispute described as 'non-event' is survivability argument not valuation argument; Simply Wall St flagging 'sizable' multi-year adjustments with timing and financial impact uncertain

→ vs aggressive: Q1 2026 $6.48B net income cited as confirmation cost spike was non-structural—conservative analyst says Trefis explicitly shows commercial medical cost trends still running higher and margin fix slipped again

→ vs aggressive: P/E normalization argument: if recovery arrives as expected, stock is fairly valued; asymmetric upside only above $22.44 EPS which requires beat-and-raise execution against already aggressive estimates

→ vs aggressive: ATR contraction and volume drying up called capitulation—conservative analyst notes same pattern appeared at $436 in July before drop to $384; declining volatility in downtrend is consolidation not reversal

→ vs aggressive: Zero retail engagement called ideal contrarian entry—conservative analyst says low engagement means no marginal buyer stepping in, rallies lack fuel; contrarian works with catalyst or extreme positioning, neither present

→ vs aggressive: Tepper/Appaloosa exit dismissed as one fund—conservative analyst notes Appaloosa is disciplined value shop; Bretton Fund also underperforming at 10.67% vs S&P 15.20%; selective weighting of Zacks articles over fund-flow evidence

→ vs aggressive: Political risk dismissed as years of rhetoric without materialization—conservative analyst cites cumulative regulatory escalation: prior authorization, drug pricing reform, MA rate pressure, IRS probe; election cycle could amplify

→ vs aggressive: Tranche structure called disciplined—conservative analyst describes it as pre-committing capital across multiple price points; 35% at $392 before technical confirms is 'aggressive posture disguised as conservative'

Initiate 12-15% of target weight at current levels ($388-$395) with a $345 stop loss, reserving additional tranches for pullbacks at $383-$388 (10-13%), $345-$355 (35%), and momentum confirmation above $412-$415 (30%)

• Forward EPS of $22.44 versus trailing $15.56 represents a 44% growth assumption baked into consensus estimates; if forward EPS drops to $20, the 17.5x forward P/E becomes 19.6x, eliminating the value argument on a single estimate revision
• Q1 2026 net income of $6.48 billion represents meaningful directional evidence as the first quarter post-trough, printing at essentially full recovery to Q1 2025 levels
• A modified tranche structure averaging 22-28% exposure post-Tranche 1 completion is consistent with a moderate-overweight rating
• Waiting for $400.07 close with volume represents waiting for 7 dollars of confirmation in a stock with $9 ATR; missing 13-18% upside to wait for three-quarters of one average day's range is poor risk-adjusted behavior
• The 15-20% starter position is inconsistent with the investment plan's Overweight rating and represents a Hold with optionality rather than meaningful conviction
• Goodwill of $130 billion on a $312 billion balance sheet means tax adjustments don't impair goodwill but do impair after-tax cash flows
• RSI at 42, MACD negative, 10 EMA declining represents a corrective phase within a structural uptrend; MACD histogram has flipped positive
• Polymarket data shows 89% probability of no Fed cuts in 2026 and 8% recession odds, providing a constructive environment for defensive large-cap compounders
• Defined risk setup with 12% downside and 13-18% upside to price target exists because of temporary earnings dislocation that has shown first signs of reversal
• The ATR of $9 makes waiting for $7 of confirmation a poor trade-off; low retail engagement removes euphoria risk but also removes enthusiasm to build on

→ vs aggressive: Forward P/E math frames consensus earnings estimates as facts rather than assumptions; the 'value' evaporates if forward EPS drops to $20 from $22.44

→ vs aggressive: ATR contraction of 27% could be coiling before the next leg down, not exhaustion before the next leg up; this is confirmation bias wearing technical analysis clothing

→ vs aggressive: The IRS dispute framing as 'absorb without breaking a sweat' is a survivability argument, not a valuation argument; multi-year tax disputes compress multiples until resolved

→ vs aggressive: Initiating 35% of target weight at 392 is too much pre-confirmation capital given medium-term technical risks and unresolved overhangs

→ vs conservative: Dismissing Q1 2026 $6.48 billion net income as 'just one data point' misses that it was the first quarter post-trough showing full recovery to Q1 2025 levels

→ vs conservative: The 'wait for 400 close with volume' trigger is too rigid; missing 13-18% upside to wait for $7 of confirmation in a stock with $9 ATR is poor risk-adjusted behavior

→ vs conservative: The 15-20% starter position is inconsistent with the investment plan's Overweight rating; it's not enough exposure to capture meaningful upside if the thesis plays out

→ vs conservative: The Tepper exit weighting is overdone; one fund's rotation doesn't define institutional consensus when other constructive voices exist

→ vs conservative: The 'great company is not a great trade' framing is philosophically clean but practically unhelpful; waiting for every overhang to clear means buying after the recovery is complete